GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Galapagos NV
Galapagos is a Belgian biotech company. Its stock price reflects a complex history, including the failure to launch its lead drug in the US and the subsequent restructuring of its R&D strategy. The chart is a story of finding a new path after a major disappointment.
Share prices of companies in the market segment - Pharma other
Galapagos is a Belgian biotech company with segments in the development and commercialization of drugs for the treatment of inflammatory diseases and oncology. We classify it in the Pharma Other sector, and the chart below shows the overall dynamics of the biotech industry.
Broad Market Index - GURU.Markets
Galapagos is a Belgian biopharmaceutical company focused on the discovery and development of small-molecule drugs for the treatment of inflammatory diseases. Its scientific developments make it a prominent player in the GURU.Markets index. The chart below represents the entire market. Find out how Galapagos compares to it.
Change in the price of a company, segment, and market as a whole per day
GLPG - Daily change in the company's share price Galapagos NV
Galapagos NV's daily price change reflects volatility in the European biotech sector. The change_co indicator measures the stock's sensitivity to research results, partnerships, and regulatory news. It serves as an essential basis for a comprehensive analysis of risks and opportunities in the pharmaceutical industry on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma other
Galapagos NV is a biotech company. This chart highlights the extreme volatility of the sector. Comparing it to GLPG, which is undergoing a complex restructuring, helps us understand its unique risk profile compared to more stable players.
Daily change in the price of a broad market stock, index - GURU.Markets
Galapagos is a Belgian biopharmaceutical company. The biotech sector is known for its high volatility. The chart below shows average daily fluctuations in the industry, allowing one to assess how Galapagos's performance compares to overall trends.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Galapagos NV
Galapagos is a Belgian biotech company. Its US-listed shares bring the dynamics of the European biotech sector to the market. These international factors make the overall picture of market volatility more complex and global.
Annual dynamics of market capitalization of the market segment - Pharma other
Galapagos NV is a European biotech company undergoing transformation following clinical trial setbacks. Its future depends on the success of its new strategy and R&D. The chart will show how the market assesses its ability to recover and compete in the challenging pharmaceutical industry.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Galapagos is a European biotech company whose stock price reflects its successes and failures in drug development. Its chart tells the story of complex scientific research, partnerships, and competition that operates by its own rules, far removed from general economic cycles.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Galapagos NV
Galapagos, a European biotech company undergoing transformation, has monthly fluctuations reflecting its success in developing new drugs after the failures of its previous flagship, as well as the strategic decisions of its new management.
Monthly dynamics of market capitalization of the market segment - Pharma other
The European biotech sector is a competitive arena where companies must constantly prove the value of their scientific platforms. The dynamics of this segment, visible in the chart, reflect investor sentiment and their reaction to research results. It is in this environment that companies like Galapagos conduct their research.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Galapagos NV is a European biotechnology company. Its shares are highly sensitive to research results and partnerships. The company's performance is volatile and driven by laboratory news rather than overall economic sentiment.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Galapagos NV
Galapagos NV is a European biotech company undergoing transformation following clinical trial setbacks. Its weekly share price performance reflects efforts to restructure its R&D pipeline and news of early-stage development of new drugs that investors are pinning their hopes on.
Weekly dynamics of market capitalization of the market segment - Pharma other
As a biotech company undergoing transformation, Galapagos may be lagging behind its sector. Investors compare it to its peers to assess the success of its new R&D strategy. The chart shows whether it is closing the gap with the industry or whether its performance continues to lag.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Galapagos is a European biotech company. Following research setbacks, its shares are under pressure. The chart below shows how internal problems and scientific setbacks can cause the company's shares to move against the market and the sector as a whole.
Market capitalization of the company, segment and market as a whole
GLPG - Market capitalization of the company Galapagos NV
The market capitalization chart of Galapagos NV, a European biotech company, is a story of high hopes and disappointments. The sharp decline reflects the failure of its lead drug candidate in clinical trials. The current valuation reflects how investors weigh its large cash hoard and early scientific programs against a loss of confidence.
GLPG - Share of the company's market capitalization Galapagos NV within the market segment - Pharma other
Galapagos NV is a European biotechnology company. Its market share and capitalization reflect both the value of its commercial products and investor valuation of its research platform following strategic shifts and partnerships.
Market capitalization of the market segment - Pharma other
The chart below shows the market capitalization of the European biotech sector. Galapagos is one of its most famous stories, full of ups and downs. The dynamics of this market reflect the high risks of pharmaceutical development. Galapagos's path is a prime example of how failure in a key trial can radically alter a company's trajectory.
Market capitalization of all companies included in a broad market index - GURU.Markets
Galapagos is a European biotech company exploring new approaches to treating inflammatory diseases. Its market capitalization reflects the complexity and risks of research in this field. The chart below shows the economic weight of science-intensive R&D platforms.
Book value capitalization of the company, segment and market as a whole
GLPG - Book value capitalization of the company Galapagos NV
Galapagos NV's book value is derived from its significant cash reserves, acquired through its partnership with Gilead, and its R&D platform. This is the foundation for discovering and developing new drugs. The chart tells the story of a European biotech company that, after failing with a key drug, is using its strong financial foundation to reboot and pursue new opportunities.
GLPG - Share of the company's book capitalization Galapagos NV within the market segment - Pharma other
Galapagos is a European biotech company, and its strength lies in R&D. The chart shows its share of real assets. These are its cutting-edge research centers, where a unique platform is used to discover new drug targets.
Market segment balance sheet capitalization - Pharma other
Galapagos NV is a European biotechnology company. Following research setbacks and restructuring, its capital intensity has decreased as it shifted its focus to earlier stages of R&D. Compared to the pharmaceutical sector, its "light" balance sheet reflects a shift from commercial ambitions to pure scientific work.
Book value of all companies included in the broad market index - GURU.Markets
Galapagos is a major European biotech company focused on developing drugs for inflammatory and kidney diseases. The company's balance sheet reflects the value of its extensive research platform and partnerships. The chart shows the capital behind this scientific machine seeking new treatments.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Galapagos NV
Galapagos NV is a European biotechnology company. Its market capitalization reflects investor valuation of its drug discovery platform and its partnerships with major pharmaceutical companies. This valuation is based on future potential, not current tangible assets, which is what creates the gap visible in the chart.
Market to book capitalization ratio in a market segment - Pharma other
Galapagos is a European biotech company focused on inflammatory diseases. Following the failure of its key drug, its valuation is heavily dependent on early development and its large cash hoard. This chart shows how the market views its ability to regenerate value from its scientific potential.
Market to book capitalization ratio for the market as a whole
Galapagos NV is a European biotech company. Its market valuation reflects investors' faith in its scientific platform and the potential of future drugs, despite past development failures. This chart demonstrates how valuation in biotech can be divorced from current financial metrics and book value in anticipation of success.
Debts of the company, segment and market as a whole
GLPG - Company debts Galapagos NV
Galapagos NV is a European biotechnology company focused on the discovery and development of drugs with novel mechanisms of action. R&D in the pharmaceutical industry is highly expensive. The company's debt strategy is part of its efforts to finance a wide range of clinical programs across various therapeutic areas.
Market segment debts - Pharma other
Galapagos NV is a European biotech company undergoing transformation following research setbacks. Its financial policy is currently focused on capital conservation and refocusing R&D. This chart shows how conservatively the company manages its balance sheet and its large cash hoard to fund its new development strategy.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Galapagos NV
Galapagos NV is a European biotech company undergoing a period of transformation following clinical trial setbacks. This chart shows its financial position during this challenging period. The capital structure reflects its efforts to refocus its research and development and effectively utilize its remaining cash.
Market segment debt to market segment book capitalization - Pharma other
Galapagos NV is a European biotechnology company with a wide range of developments. The chart illustrates the collective debt policy in the pharmaceutical sector. It allows one to assess how the company balances funding multiple research programs with maintaining financial stability compared to other industry players.
Debt to book value of all companies in the market
Galapagos NV is a European biotechnology company. The chart illustrates the collective debt policy for the entire US market. This allows one to assess how the financial strategies of large non-US companies listed in the US relate to the general economic trends characteristic of US businesses.
P/E of the company, segment and market as a whole
P/E - Galapagos NV
This chart for Galapagos NV, a European biotech company, reflects its difficult journey following clinical trial setbacks. The market's low valuation of its potential profits reflects investor skepticism. The trend reflects whether the market believes the company can recover thanks to its research strength and ample cash reserves.
P/E of the market segment - Pharma other
This chart reflects the average valuation for the European biotech sector—the benchmark for Galapagos. Comparing this struggling company's valuation to the industry average clearly demonstrates investor skepticism. A below-average valuation suggests the market doesn't yet believe it can recover, despite its scientific potential.
P/E of the market as a whole
Galapagos NV is a European biotech company undergoing transformation following setbacks in developing a key drug. Its future depends on new research. This chart of overall market sentiment shows whether investors are willing to give a second chance. During periods of optimism, they may believe in a new strategy, but in times of decline, they will be extremely skeptical of companies with a history of failure.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Galapagos NV
Galapagos NV is a European biotech company undergoing transformation and searching for new promising drugs after previous developments failed. The company's valuation is based on confidence in its scientific platform. This chart shows how confident analysts are in the company's ability to discover and successfully develop new blockbuster drugs.
%20P%2FE%20Galapagos%20NV&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Galapagos-NV&v=1772631869111 "Chart of the company's future (projected) P/E Galapagos NV")
Future (projected) P/E of the market segment - Pharma other
Galapagos NV is a European biotech company focused on developing drugs for inflammatory diseases and fibrosis. Its valuation relative to other biotechs reflects the market's opinion of its scientific platform and its ability to recover from recent clinical trial setbacks. This is an indicator of confidence in its long-term potential.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-other&v=1772631869125 "Future (projected) P/E graph of the market segment - Pharma other")
Future (projected) P/E of the market as a whole
Galapagos is a European biotech company that, following setbacks with its key drug, is searching for a new strategy. Its valuation reflects its large cash reserves and hopes for future developments. This chart shows the company's overall risk appetite. It helps understand whether investors are willing to give biotech companies a second chance in difficult times, believing in their scientific potential.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772631869140 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Galapagos NV
Galapagos NV is a European biotechnology company focused on the discovery and development of small-molecule drugs with novel mechanisms of action. Its financial performance, as reflected in the chart, is driven by the success of clinical trials and partnerships with major pharmaceutical companies for drug commercialization.
Profit of companies in the market segment - Pharma other
Galapagos NV is a European biotechnology company focused on research and development of drugs for inflammatory diseases and fibrosis. This chart reflects the financial health of the pharmaceutical sector as a whole. It helps assess how difficult it is for smaller R&D companies to compete with giants and make their drugs profitable.
Overall market profit
Galapagos NV is a European biotechnology company focused on research and development of new drugs. Following the failure of a key drug, the company is in a transformational phase. Its future depends on the effectiveness of R&D and strategic decisions, not on the state of corporate profits in the broader economy, as this chart shows.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Galapagos NV
Galapagos NV is a European biotech company that, following a series of development setbacks, is in the process of rebuilding its research portfolio. Its future profit forecast reflects analysts' skepticism or optimism regarding its new strategy and ability to develop commercially successful drugs based on its scientific platforms.
%20profit%20of%20the%20company%20Galapagos%20NV&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Galapagos-NV&v=1772631869271 "Graph of future (projected) profit of the company Galapagos NV")
Future (predicted) profit of companies in the market segment - Pharma other
Galapagos NV is a European biotech company that, after a series of research setbacks, is undergoing a transformation, focusing on oncology and immunology. The company's future depends on the success of its new strategy and developments. This chart shows forecasts for the pharmaceutical sector. It provides context for assessing the complexity of Galapagos's task of returning to a growth trajectory in this industry.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-other&v=1772631869301 "Graph of future (predicted) profits of companies in a market segment - Pharma other")
Future (predicted) profit of the market as a whole
Galapagos NV is a European biotechnology company developing innovative medicines. The total return forecast, shown in this chart, influences the overall investment environment. Positive economic expectations encourage capital inflows into risky but promising industries like biotechnology, helping Galapagos fund its research.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772631869315 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Galapagos NV
Galapagos is a European biotech company developing drugs for inflammatory diseases. This chart shows how the market values its revenue, which includes both sales of approved drugs and payments from partners. It reflects confidence in its scientific platform.
P/S market segment - Pharma other
Galapagos NV is a Belgian biopharmaceutical company focused on the discovery and development of small-molecule drugs with novel mechanisms of action. This chart reflects the average valuation in the pharmaceutical sector. It provides an insight into the market perception of the company's scientific research and its extensive pipeline of developments in inflammatory and fibrotic diseases.
P/S of the market as a whole
Galapagos NV is a European biotechnology company focused on the discovery and development of small-molecule drugs with novel mechanisms of action. Its financial performance is dependent on the success of clinical trials and partnerships. This chart provides investors with an overall valuation framework against which to analyze the risks and potential of the biotechnology sector.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Galapagos NV
Galapagos NV is a European biotech company developing drugs for inflammatory and fibrotic diseases. Its future revenue depends on the success of its partnerships and clinical programs. The chart shows how investors view its scientific platform and ability to bring new drugs to market after recent setbacks.
%20P%2FS%20Galapagos%20NV&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Galapagos-NV&v=1772631869455 "The graph of the company's future (projected) P/S Galapagos NV")
Future (projected) P/S of the market segment - Pharma other
Galapagos NV is a European biotechnology company focused on the discovery and development of small-molecule drugs with novel mechanisms of action, primarily in immunology and inflammation. This chart shows how investors view its scientific platform and the potential of future drugs compared to other pharmaceutical companies.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20other&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-other&v=1772631869519 "Future (projected) P/S market segment graph - Pharma other")
Future (projected) P/S of the market as a whole
This shows the overall level of investor optimism in the pharmaceutical industry. For Galapagos NV, a biotech company developing drugs for inflammatory and fibrotic diseases, this indicates the market's willingness to fund research. Confidence in future growth allows the company to continue its research programs in search of new treatments.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772631869642 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Galapagos NV
Galapagos NV is a European biotechnology company focused on the discovery and development of small-molecule drugs with novel mechanisms of action. This chart shows revenue from royalties on commercially sold products and payments from co-development partners. Its growth will depend on the success of clinical trials and the launch of new drugs.
Sales of companies in the market segment - Pharma other
Galapagos NV is a European biotechnology company focused on the discovery and development of small-molecule drugs with novel mechanisms of action. This chart illustrates the overall dynamics of the pharmaceutical industry. Galapagos' research platform is focused on finding innovative treatments for inflammatory and fibrotic diseases.
Overall market sales
Galapagos NV is a European biotechnology company focused on research and development of new drugs. Its value is dependent on progress in clinical trials. The overall economic situation, reflected in this chart, influences the amount of funding available for R&D in the pharmaceutical industry and the strategic decisions of major partners.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Galapagos NV
Galapagos NV is a European biotechnology company focused on the discovery and development of small-molecule drugs with novel mechanisms of action. Its future depends on the success of clinical trials in immunology and oncology. This chart reflects analysts' assessments of the scientific potential of the Galapagos platform and the commercial prospects of its experimental drugs.
%20sales%20of%20the%20company%20Galapagos%20NV&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Galapagos-NV&v=1772631869828 "Schedule of future (projected) sales of the company Galapagos NV")
Future (projected) sales of companies in the market segment - Pharma other
Galapagos NV is a Belgian biotechnology company focused on the discovery and development of small-molecule drugs with novel mechanisms of action. This forecast reflects expectations for the entire pharmaceutical sector. It helps understand the overall investment and research trends that shape the environment for innovative companies like Galapagos.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-other&v=1772631869851 "Schedule of future (projected) sales of companies in the market segment - Pharma other")
Future (projected) sales of the market as a whole
Galapagos NV is a European biotechnology company focused on the discovery and development of drugs with novel mechanisms of action. Its market capitalization is dependent on clinical trial results. The overall economic environment, reflected in this chart, influences the level of investment in research-intensive industries and the willingness of large pharmaceutical companies to engage in partnerships and acquisitions.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772631869868 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Galapagos NV
Galapagos is a European biotech company undergoing transformation. This chart reflects its financial position following a strategic review. The company's profitability now depends on sales of its approved rheumatoid arthritis drug and the success of new research programs designed to expand its pipeline.
Market segment marginality - Pharma other
Galapagos NV is a European biotechnology company focused on the discovery and development of small-molecule drugs with novel mechanisms of action. Its financial performance is driven by the success of its partnerships and clinical programs. This metric provides insight into its operating model and level of investment in R&D compared to other biopharmaceutical companies.
Market marginality as a whole
Galapagos NV is a European biotechnology company focused on the research and development of innovative medicines. This total market return chart does not reflect its core business. Galapagos's success depends on its scientific pipeline, partnerships with major pharmaceutical companies, and its ability to bring promising molecules to commercialization.
Employees in the company, segment and market as a whole
Number of employees in the company Galapagos NV
Galapagos is a European biotech company undergoing transformation following clinical trial failures. This chart reflects the restructuring of its scientific team. The headcount dynamics tell a story of strategy revisions, program cuts, and investments in new promising areas.
Share of the company's employees Galapagos NV within the market segment - Pharma other
Galapagos NV is a European biotechnology company focused on the discovery and development of small-molecule drugs. This chart shows its importance as a research hub and employer in the European biotech industry. It reflects the significant share of research scientists and clinical development specialists the company employs to develop innovative therapies.
Number of employees in the market segment - Pharma other
Galapagos NV is a Belgian biotechnology company focused on the discovery, development, and commercialization of innovative drugs with novel mechanisms of action, primarily for the treatment of inflammatory diseases. This chart highlights the company's involvement in innovative pharmaceuticals, showing how research in immunology and inflammation is leading to the development of new treatments.
Number of employees in the market as a whole
Galapagos NV is a European biotechnology company focused on research and development of new drugs. It is a classic example of an innovation-driven industry, where it takes years and significant investment to bring a product to market. This investment creates jobs for the scientific elite, laying the foundation for future economic growth and competitiveness.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Galapagos NV (GLPG)
Galapagos is a European biotech company undergoing transformation. This chart may reflect a challenging period for the company. The capitalization per employee ratio is important for analyzing the effectiveness of the restructuring and how the market perceives the new R&D strategy and the potential of the remaining drugs in development.
%20of%20the%20company%20Galapagos%20NV%20(GLPG)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Galapagos-NV-GLPG&v=1772631870224 "Chart of market capitalization per employee (in thousands of dollars) of the company Galapagos NV (GLPG)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma other
Galapagos NV (GLPG) is a European biotech company that, following the failure of a key drug, is refocusing its R&D on new platforms (e.g., CAR-T cell therapy). This chart shows the industry average cost per employee. It helps assess how the market values their R&D platform and significant cash reserves per scientist during this transformation period.
%20by%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-other&v=1772631870229 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma other")
Market capitalization per employee (in thousands of dollars) for the overall market
Galapagos NV is a European biotechnology company focused on the discovery and development of small-molecule drugs. This chart reflects the market value of one employee, highlighting the importance of the company's R&D platform and pipeline.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772631870248 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Galapagos NV (GLPG)
Galapagos NV is a European biotechnology company. After R&D setbacks, the company refocused by acquiring a cell therapy business. This chart reflects this complex transition. It shows how the company is trying to transform its R&D costs (loss per employee) into a profitable business, a highly challenging task.
%20Chart%20Galapagos%20NV%20(GLPG)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Galapagos-NV-GLPG&v=1772631870271 "Company Profit Per Employee (in thousands of dollars) Chart Galapagos NV (GLPG)")
Profit per employee (in thousands of dollars) in the market segment - Pharma other
Galapagos (GLPG) is an R&D platform (biotech). This chart shows the benchmark for Pharma (R&D). The average profit per employee in this sector (venture R&D) is *negative*. This benchmark reflects the "burn" of money. The entire sector is an R&D race, spending billions on elite scientists in hopes of a "blockbuster."
%20in%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-other&v=1772631870284 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma other")
Profit per employee (in thousands of dollars) for the market as a whole
Galapagos NV is a European biotech company. After R&D setbacks, the company shifted its strategy by acquiring cell therapy (CAR-T) businesses. This chart reflects a complex transition. It likely represents a loss per employee, but investors are watching to see if this dynamic changes as it integrates new, potentially breakthrough cell therapy technologies.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772631870300 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Galapagos NV (GLPG)
Galapagos NV is a European biotechnology company developing innovative medicines. This chart illustrates the complex dynamics of the biotech industry. It reflects both the commercialization success of some drugs and the R&D expenditures on others, demonstrating the company's overall effectiveness in turning science into revenue.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Galapagos-NV-GLPG&v=1772631870347 "Sales chart per company employee Galapagos NV (GLPG)")
Sales per employee in the market segment - Pharma other
Galapagos NV is a European biotechnology company focused on developing drugs for inflammatory diseases and fibrosis. This chart shows the average revenue per employee in this segment. It helps assess how productive Galapagos' scientific and commercial teams are compared to their peers in the highly competitive pharmaceutical industry.
Sales per employee for the market as a whole
Galapagos NV is a European biotech company undergoing transformation and exploring new R&D avenues after a series of setbacks. This chart shows the revenue (primarily partnership fees) generated by their large R&D staff. Currently, this is more of an "expense" indicator until the company brings new, successful products to market.
Short shares by company, segment and market as a whole
Shares shorted by company Galapagos NV (GLPG)
Galapagos NV is a European biotech company that suffered a severe blow after the failure of its key drug (Filgotinib) in the US. The company is now trying to restructure its R&D. This chart illustrates the high market skepticism: investors don't believe the company will be able to create new successful drugs after such a high-profile failure.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Galapagos-NV-GLPG&v=1772631870493 "Short Shares Chart for the Company Galapagos NV (GLPG)")
Shares shorted by market segment - Pharma other
Galapagos NV is a European biotech company that, after failing to develop arthritis drugs, shifted its focus to oncology and CAR-T therapy. This chart reflects the total short position in the biotech sector. High values indicate general investor skepticism about the success of risky clinical trials, especially for companies changing their strategy.
Shares shorted by the overall market
Galapagos (GLPG) is a European biotech company. This indicator (`Short_All`) is a mirror of market fear. When it rises, investors panic and dump risk, especially biotech. This pessimism, visible on the chart, is weighing on GLPG shares, whose R&D prospects require long-term confidence.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Galapagos NV (GLPG)
Galapagos is a European biotech company focused on R&D. For a stock whose value is so heavily tied to future lab success, investor sentiment is crucial. This chart measures the momentum of that sentiment. It shows when investor expectations for clinical data are peaking (overbought) or when the market is losing confidence in the pipeline (oversold).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Galapagos-NV-GLPG&v=1772631870612 "RSI 14 indicator chart for the company's stock Galapagos NV (GLPG)")
RSI 14 Market Segment - Pharma other
Galapagos NV is a European clinical-stage biotech company. After experiencing setbacks with its key drug, the company is restructuring its R&D pipeline, focusing on immunology and oncology. This chart shows the overall sentiment in the biotech sector. It helps assess whether the entire speculative industry is overheated or oversold.
RSI 14 for the overall market
Galapagos NV (GLPG) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast GLPG (Galapagos NV)
Galapagos NV is a European biotech company that, after setbacks in rheumatology, refocused its research on oncology and immunology using CAR-T technology. This chart shows the average price target from analysts, reflecting their views on the new strategy and scientific potential.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-GLPG-Galapagos-NV&v=1772631870731 "A chart showing analyst consensus forecasts for the expected stock price. GLPG (Galapagos NV)")
The difference between the consensus estimate and the actual stock price GLPG (Galapagos NV)
Galapagos (GLPG) is a European biotech company that, after a failed blockbuster, is undergoing a restructuring, using its large cash hoard to acquire new assets. This chart shows their restructuring valuation. It measures the gap between the price and the consensus target, reflecting whether analysts believe in their new R&D strategy.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-GLPG-Galapagos-NV&v=1772631870748 "A chart showing the difference between the consensus forecast and the actual stock price. GLPG (Galapagos NV)")
Analyst consensus forecast for stock prices by market segment - Pharma other
Galapagos NV is a Belgian biotech company that, after R&D setbacks, pivoted to cell therapy (CAR-T) for cancer treatment. This chart shows analysts' overall expectations for the pharmaceutical sector. It reflects whether experts believe the company's transformation and its new oncology programs will be successful.
Analysts' consensus forecast for the overall market share price
Galapagos NV (GLPG) is a European biotech company (previously hot, now in a renaissance phase). It's a risky R&D story. This chart of overall market sentiment is important. Optimism = the market is willing to burn money funding unprofitable biotechs. Pessimism = risk aversion, and companies with R&D failures lose investor confidence.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Galapagos NV
Galapagos NV is a European biotech company undergoing a complex transformation. Following the failure of their flagship drug, they are using their massive cash hoard to acquire and develop new assets in oncology and immunology. This chart is an assessment of their second chance. It reflects the market's confidence in their new R&D strategy and their ability to spend money wisely.
AKIMA Market Segment Index - Pharma other
Galapagos NV (GLPG) is a European biotech that (following the failure of its key drug) is undergoing a profound transformation, using its vast cash reserves to acquire new assets (CAR-T). This composite metric evaluates R&D. The graph shows the segment average. This benchmark: how does Galapagos' transformative R&D model differentiate it from the average pharma company?
The AKIM Index for the overall market
Galapagos is a European biotech company that pivoted to cell therapy (CAR-T) and small molecules after a strategic shift. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this cash-rich company, with its new goals, stacks up against broader economic trends.
